| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MPL Mutation Analysis : 92476
Test CodeMPL or 92476
Alias/See Also
Polycythemia Vera, ET, PMF, PV, Primary Myelofibrosis, Essential Thrombocythemia, Myeloproliferative neoplasm
CPT Codes
81338
Instructions
Lavender (EDTA) peripheral blood OR bone marrow (EDTA). Also acceptable: whole blood or bone marrow in Sodium heparin (green-top tube).
Transport Container
Do not freeze. Transport 4 mL whole blood (Min: 3 mL) OR 3 mL bone marrow (Min: 1 mL).
Transport Temperature
Refrigerated.
Specimen Stability
Ambient: 7 days; Refrigerated: 7 days; Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
.
Methodology
Polymerase Chain Reaction- based DNA Sequencing
Setup Schedule
Sunday - Saturday
Report Available
5-7 days (From receipt at performing laboratory)
Limitations
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.
This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.
Reference Range
Not detected
Clinical Significance
This DNA-based assay tests leukocytes from blood or bone marrow aspirate for mutations in exon 10 of the thrombopoietin receptor (MPL), including codons 505 and 515, using an advanced DNA sequencing method. Mutations at these sites in MPL are associated with myeloproliferative neoplasms, particularly essential thrombocythemia and primary myelofibrosis.
Performing Laboratory
Quest Diagnostics
